Targeting NSD2-mediated SRC-3 liquid–liquid phase separation sensitizes bortezomib treatment in multiple myeloma
The mechanisms behind acquired resistance to the proteasome inhibitor bortezomib in multiple myeloma remain to be elucidated. Here, the authors show that the histone methyltransferase NSD2 stabilized SRC-3 protein levels, promotes its phase separation and alters H3K36me2 at certain gene promoters re...
Saved in:
Main Authors: | Jing Liu, Ying Xie, Jing Guo, Xin Li, Jingjing Wang, Hongmei Jiang, Ziyi Peng, Jingya Wang, Sheng Wang, Qian Li, Linquan Ye, Yuping Zhong, Qiguo Zhang, Xiaozhi Liu, David M. Lonard, Jin Wang, Bert W. O’Malley, Zhiqiang Liu |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/695b13f642e84ed19489e07ffe4eec6b |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A genome-scale CRISPR Cas9 dropout screen identifies synthetically lethal targets in SRC-3 inhibited cancer cells
by: Yosi Gilad, et al.
Published: (2021) -
Steroid receptor coactivator 3 (SRC-3/AIB1) is enriched and functional in mouse and human Tregs
by: Bryan C. Nikolai, et al.
Published: (2021) -
AntagomiR-19a Induced Better Responsiveness to Bortezomib in Myeloma Cell Lines
by: Azam Kazemi, et al.
Published: (2021) -
Relationship between Serum Bortezomib Concentration and Emergence of Diarrhea in Patients with Multiple Myeloma and/or AL Amyloidosis
by: Yuki Fujimoto, et al.
Published: (2021) -
Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma
by: Cinzia Federico, et al.
Published: (2020)